Laurent J, Belghiti D, Bruneau C, Lagrue G
Am J Nephrol. 1987;7(3):198-202. doi: 10.1159/000167463.
Treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) was first used in glomerulonephritis (GN) in 1966 but its efficiency is still debated. We studied the antiproteinuric effect of such a treatment in a double-blind study. 29 GN patients with normal renal function (17 membranoproliferative GN, 12 IgA GN) were randomly assigned to receive 100 mg/day of diclofenac or placebo for at least 2 months. There was a significant antiproteinuric effect of diclofenac versus placebo with a fall of 70% in the diclofenac group versus 6% in the placebo group (p less than 0.001 with the Mann-Whitney test). The median was 3 mg/min at onset and 2.45 mg/min after 2 months treatment with the placebo. In the diclofenac group, it was 2.2 and 0.95 mg/min, respectively (p less than 0.01). Diclofenac did not significantly increase creatinine levels. Gastric irritation was noted only once. This study establishes the short-term antiproteinuric action of diclofenac. Whether this action affects the final outcome is not yet determined.
非甾体抗炎药（NSAIDs）治疗于1966年首次用于肾小球肾炎（GN），但其疗效仍存在争议。我们在一项双盲研究中研究了这种治疗的抗蛋白尿作用。29例肾功能正常的GN患者（17例膜增生性GN，12例IgA GN）被随机分配接受100mg/天的双氯芬酸或安慰剂治疗至少2个月。与安慰剂相比，双氯芬酸有显著的抗蛋白尿作用，双氯芬酸组下降了70%，而安慰剂组下降了6%（曼-惠特尼检验，p<0.001）。安慰剂治疗2个月时，蛋白尿中位数起始时为3mg/min，治疗后为2.45mg/min。在双氯芬酸组，分别为2.2mg/min和0.95mg/min（p<0.01）。双氯芬酸未显著提高肌酐水平。仅出现过一次胃部刺激症状。本研究证实了双氯芬酸的短期抗蛋白尿作用。该作用是否会影响最终结局尚未确定。
